Switch to:
Also traded in: Germany, Italy, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.90
CTIC's Cash to Debt is ranked lower than
79% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. CTIC: 0.90 )
Ranked among companies with meaningful Cash to Debt only.
CTIC' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 1.21 Max: No Debt
Current: 0.9
Equity to Asset -0.37
CTIC's Equity to Asset is ranked lower than
95% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CTIC: -0.37 )
Ranked among companies with meaningful Equity to Asset only.
CTIC' s Equity to Asset Range Over the Past 10 Years
Min: -2.7  Med: -0.11 Max: 0.95
Current: -0.37
-2.7
0.95
F-Score: 1
Z-Score: -48.30
M-Score: -4.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1887.79
CTIC's Operating margin (%) is ranked lower than
82% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. CTIC: -1887.79 )
Ranked among companies with meaningful Operating margin (%) only.
CTIC' s Operating margin (%) Range Over the Past 10 Years
Min: -123250  Med: -12055.10 Max: -119.75
Current: -1887.79
-123250
-119.75
Net-margin (%) -1957.12
CTIC's Net-margin (%) is ranked lower than
83% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. CTIC: -1957.12 )
Ranked among companies with meaningful Net-margin (%) only.
CTIC' s Net-margin (%) Range Over the Past 10 Years
Min: -169773.75  Med: -13740.68 Max: -123.26
Current: -1957.12
-169773.75
-123.26
ROE (%) -1081.79
CTIC's ROE (%) is ranked lower than
98% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. CTIC: -1081.79 )
Ranked among companies with meaningful ROE (%) only.
CTIC' s ROE (%) Range Over the Past 10 Years
Min: -1010.2  Med: -292.63 Max: -124.54
Current: -1081.79
-1010.2
-124.54
ROA (%) -130.06
CTIC's ROA (%) is ranked lower than
89% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. CTIC: -130.06 )
Ranked among companies with meaningful ROA (%) only.
CTIC' s ROA (%) Range Over the Past 10 Years
Min: -261.37  Med: -120.92 Max: -51.06
Current: -130.06
-261.37
-51.06
ROC (Joel Greenblatt) (%) -1843.08
CTIC's ROC (Joel Greenblatt) (%) is ranked lower than
69% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. CTIC: -1843.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CTIC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2348.37  Med: -1789.88 Max: -222.8
Current: -1843.08
-2348.37
-222.8
EBITDA Growth (3Y)(%) -29.40
CTIC's EBITDA Growth (3Y)(%) is ranked lower than
82% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. CTIC: -29.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CTIC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -84  Med: -29.85 Max: 26.4
Current: -29.4
-84
26.4
EPS Growth (3Y)(%) -43.20
CTIC's EPS Growth (3Y)(%) is ranked lower than
89% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CTIC: -43.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CTIC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -82.6  Med: -30.00 Max: 24.6
Current: -43.2
-82.6
24.6
» CTIC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

CTIC Guru Trades in Q4 2014

Jim Simons 587,916 sh (-41.84%)
» More
Q1 2015

CTIC Guru Trades in Q1 2015

Paul Tudor Jones 86,900 sh (New)
Jim Simons Sold Out
» More
Q2 2015

CTIC Guru Trades in Q2 2015

Jim Simons 561,124 sh (New)
Paul Tudor Jones 68,600 sh (-21.06%)
» More
Q3 2015

CTIC Guru Trades in Q3 2015

Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CTIC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 28.00
CTIC's P/S is ranked lower than
72% of the 620 Companies
in the Global Biotechnology industry.

( Industry Median: 10.07 vs. CTIC: 28.00 )
Ranked among companies with meaningful P/S only.
CTIC' s P/S Range Over the Past 10 Years
Min: 0.06  Med: 125.00 Max: 4609.09
Current: 28
0.06
4609.09
Current Ratio 1.46
CTIC's Current Ratio is ranked lower than
82% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. CTIC: 1.46 )
Ranked among companies with meaningful Current Ratio only.
CTIC' s Current Ratio Range Over the Past 10 Years
Min: 0.38  Med: 2.77 Max: 24.99
Current: 1.46
0.38
24.99
Quick Ratio 1.39
CTIC's Quick Ratio is ranked lower than
79% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CTIC: 1.39 )
Ranked among companies with meaningful Quick Ratio only.
CTIC' s Quick Ratio Range Over the Past 10 Years
Min: 0.38  Med: 2.77 Max: 24.96
Current: 1.39
0.38
24.96
Days Inventory 1.00
CTIC's Days Inventory is ranked higher than
100% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. CTIC: 1.00 )
Ranked among companies with meaningful Days Inventory only.
CTIC' s Days Inventory Range Over the Past 10 Years
Min: 16.31  Med: 1080.10 Max: 8925.18
Current: 1
16.31
8925.18
Days Sales Outstanding 32.14
CTIC's Days Sales Outstanding is ranked higher than
78% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. CTIC: 32.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
CTIC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.47  Med: 41.83 Max: 834.94
Current: 32.14
2.47
834.94
Days Payable 4.00
CTIC's Days Payable is ranked lower than
91% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. CTIC: 4.00 )
Ranked among companies with meaningful Days Payable only.
CTIC' s Days Payable Range Over the Past 10 Years
Min: 1049.43  Med: 2592.11 Max: 49126.02
Current: 4
1049.43
49126.02

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.16
CTIC's Price/Median PS Value is ranked higher than
95% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. CTIC: 0.16 )
Ranked among companies with meaningful Price/Median PS Value only.
CTIC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.02  Med: 1.17 Max: 2903.68
Current: 0.16
0.02
2903.68
Price/Graham Number 0.76
CTIC's Price/Graham Number is ranked higher than
75% of the 286 Companies
in the Global Biotechnology industry.

( Industry Median: 2.11 vs. CTIC: 0.76 )
Ranked among companies with meaningful Price/Graham Number only.
CTIC' s Price/Graham Number Range Over the Past 10 Years
Min: 0.01  Med: 1.00 Max: 28.89
Current: 0.76
0.01
28.89
Earnings Yield (Greenblatt) (%) -35.50
CTIC's Earnings Yield (Greenblatt) (%) is ranked lower than
81% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. CTIC: -35.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CTIC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -64.18  Med: 0.00 Max: 0
Current: -35.5
-64.18
0

More Statistics

Revenue(Mil) $44
EPS $ -0.81
Beta0.40
Short Percentage of Float8.01%
52-Week Range $0.80 - 2.94
Shares Outstanding(Mil)231.72

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 38 8 162
EPS($) -0.54 -0.78 -0.20
EPS without NRI($) -0.54 -0.78 -0.20

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CEPR.Germany, CTIC.Italy, 0QUJ.UK,
CTI Biopharma Corp was incorporated in Washington in 1991. The Company is a biopharmaceutical company focused on the acquisition, development and commercialization of less toxic and more effective ways to treat cancer. The Company is engaged in commercializing PIXUVRI (pixantrone) in the European Union, or the E.U., for multiply relapsed or refractory aggressive non-Hodgkin lymphoma, or NHL, and conducting a Phase 3 clinical trial program of pacritinib for the treatment of myelofibrosis that will support regulatory submission for approval in the United States, or the U.S., and Europe. PIXUVRI is a novel aza-anthracenedione derivative that is structurally related to anthracyclines and anthracenediones, but does not appear to be associated with the same level of cardiotoxic effects. In May 2012, it expanded its late-stage pipeline of product candidates with the acquisition of pacritinib, an oral inhibitor of both Janus Kinase 2, or JAK2, and FMS-like tyrosine kinase, or FLT3, which demonstrated meaningful clinical benefits and good tolerability in myelofibrosis patients in Phase 2 clinical trials. The Company faces competition from a variety of companies focused on developing oncology drugs. It competes with large pharmaceutical companies and with other specialized biotechnology companies. The research, development, testing, manufacture, labeling, promotion, advertising, distribution and marketing, among other things, of its products are extensively regulated by governmental authorities in the U.S. and other countries.
» More Articles for CTIC

Headlines

Articles On GuruFocus.com
Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG Ther Jun 01 2015 
Weekly CEO Sells Highlight: Groupon Inc., Cell Therapeutics Inc., Standard Pacific Corp and Dollar G Mar 24 2014 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Feb 25 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 50,000 Shares Jan 28 2011 
Weekly CEO Sells Highlight: CTIC, DDR, UNM, BRCM, TC Jan 09 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 250,000 Shares Jan 03 2011 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 200,000 Shares Dec 17 2010 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 150,000 Shares Dec 10 2010 
Cell Therapeutics Inc. (CTIC) CEO James A Bianco sells 100,000 Shares Nov 05 2010 

More From Other Websites
CTI BioPharma Provides Update On Investigational Agent Pacritinib Feb 08 2016
CTI BioPharma Corp. breached its 50 day moving average in a Bearish Manner : February 3, 2016 Feb 03 2016
CTI BioPharma (CTIC) in Focus: Stock Moves 5.9% Higher Feb 01 2016
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jan 28 2016
CTI BioPharma Corp. – Value Analysis (NASDAQ:CTIC) : January 20, 2016 Jan 20 2016
CTI BioPharma Corp. breached its 50 day moving average in a Bearish Manner : January 20, 2016 Jan 20 2016
CTI BioPharma Appoints Matthew Perry To Board Of Directors Jan 13 2016
CTI BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers Jan 13 2016
CTI BioPharma Appoints Matthew Perry To Board Of Directors Jan 13 2016
3 Biotech Stocks Under $10 to Trade for Big Breakouts Jan 13 2016
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jan 11 2016
CTI BioPharma Announces Positive Progress Of Lead Clinical Programs And General Outlook For... Jan 11 2016
CTI BIOPHARMA CORP Files SEC form 8-K, Other Events Jan 08 2016
CTI BioPharma And Baxalta Complete Submission Of New Drug Application For Pacritinib For Unmet... Jan 05 2016
CTI BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Dec 29 2015
Identifying Opportunity, Placing Risk - Analyst Notes on CTI BioPharma, Vitae Pharmaceuticals,... Dec 24 2015
CTI BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers Dec 24 2015
CTI BioPharma Corp. Earnings Analysis: Q3, 2015 By the Numbers Dec 22 2015
A Change in Tides - Complementary Research on CTI BioPharma, Flex Pharma, Comstock Resources and... Dec 16 2015
CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX® Dec 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK